HIGHLIGHTS
- who: Thilo Zander from the DivisionUniversity of Bern, Bern, Switzerland have published the research: Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial, in the Journal: (JOURNAL) of 12/09/2022
- what: The reasons for this were acute financial constraints at SAKK, together with slower-than-expected accrual because of increased availability of pomalidomide-containing triplets and the entire lack of external financial funding from commercial sources supporting this trial aiming to reduce pomalidomide drug treatment costs.
SUMMARY
The primary study endpoint was . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.